Bluebird bio, Bristol-Myers` multiple myeloma therapy shows promise in early study
(Reuters Health)

Bluebird bio Inc and Bristol-Myers Squibb Co on Monday reported encouraging initial data from an ongoing early-stage study testing their experimental therapy for multiple myeloma in patients who did not respond to prior treatments.